The immune cells trained to fight off the body's invaders can become defective. It's what allows cancer to develop. So most cancer immunotherapy research has targeted these so-called effector T cells.

But a new study steps back and considers: What if the problem isn't with the effector T cells, but starts higher up the cellular chain?

查看原文：https://www.michiganmedicine.org/health-lab/how-poorly-explored-immune-cell-may-impact-cancer-immunity-and-immunotherapy